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Leprosy Type 1 Reactions (T1R) are immune-mediated events leading to nerve damage and
preventable disabilities. They manifest clinically with erythema and oedema of skin lesions
and tender peripheral nerves with loss of function. Up to 30% of patients with borderline
leprosy are affected by T1R.1 Although T1R can occur at any time, the frequency is higher in
the first six months of MDT treatment.2 T1R are treated with corticosteroids.3 Clinical trials
are needed to assess not only efficacious and safe second line drugs but also to assess the best
regimens of prednisolone in terms of dosage, length of treatment and rate of decrease.
A tool which enables clinicians to assess the severity of T1R is useful in defining
outcomes in clinical trials. The lack of uniformity surrounding interpretation of data has
hindered development of internationally accepted treatment protocols and guidelines, while
also making trialling of new therapeutic agents difficult. Using a validated clinical severity
scale for leprosy reactions improves research quality and provides a tool to promote
uniformity and comparability of research.
A Severity Scale for T1R, based on the INFIR clinical severity scoring system, was
developed and prospectively validated in Bangladesh and Brazil.4 The scale consists of 21
items to assesses three components of T1R.4 The first section looks at skin involvement using
number of affected lesions, the degree of inflammation and the presence of peripheral oedema
(Score A). The second section is a measurement of sensory function of the nerves by using
graded Semmes-Weinstein monofilaments (SWM) to assess sensation in the hands and feet,
and cotton wool for corneal sensation (Score B). The third section uses a standard measure of
muscle power (MRC grading) to assess the motor function of the nerves of the face, hands and
feet (Score C). The sum of the total for each section (A, B, and C) gives the overall severity
scale score with a range of 0–63 (Appendix 1). The maximum score possible for sections A,
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B and C are 9, 24 and 30 respectively. A mild T1R is characterised by a score of 4 or less; a
moderate T1R by a score between 4·5 and 8·4 and a severe T1R is a score of 9 or more.
This Severity Scale for T1R has so far been used in clinical trials on intravenous
methylprednisolone in Nepal,5 on azathioprine in India6 and in the on-going TENLEP studies
in India.7 In order to use such a scale in a trial on ciclosporin efficacy in T1R, we needed to
validate it in the population in which the study was to be conducted. The validation exercise
in Ethiopian patients is described here.
Methods
Patients presenting with signs and symptoms of T1R at the Leprosy Clinic at ALERT
Hospital in Addis Ababa were recruited between February 2010 and August 2010. Ethical
approval was granted by the London School of Hygiene and Tropical Medicine (5426/Dec
2008) and ALERT and AHRI Ethical Review Committee (PO22/08).
Inclusion criteria were patients aged 18 or more presenting with T1R. Patients unable or
unwilling to give informed consent were excluded. All patients gave informed consent to
participate in the assessment. Patients could be presenting with new T1R or be on treatment
for T1R. Patients were examined independently, on the same day, by a health worker who
was trained to use the scale and by an experienced leprologist who categorised the reaction as
mild, moderate or severe. Neither assessor was aware of the result of the others examination.
The scoring was done on pre-prepared scoring sheet which listed skin finding and results of
voluntary muscle testing and sensory testing.
The results were entered into an Access database and the data was analysed using the
Statistical Package for Social Sciences (SPSS version 20).
Results
135 patients with T1R were examined using the T1R severity scale assessment sheet.
The severity of the T1R was categorised by the specialist as mild in 43 (32%), moderate in
34 (25%) and severe in 38 (28%) patients. Another 20 patients (15%) with no signs of active
T1R but on prednisolone treatment were assessed. Median scores for each category were
none ¼ 0 ^ 1·69; mild ¼ 3·0 ^ 2·55; moderate ¼ 6·5 ^ 2·55 and severe ¼ 19·0 ^ 9·70.
The box-plot in Figure 1 illustrates the score distribution clearly.
The differences in the scores between the group with no active reaction and the mild
group, the mild group and the moderate group and the moderate group and the severe group
were all statistically significance (P , 0·001, Independent sample t test). The group of
patients graded as having severe TIR had the widest confidence interval, and there is an
overlap between each category.
Discussion
This is the first report of the use of the T1R Severity Scale in Ethiopia and it shown that it is a
valid tool for assessing the severity of T1R in Ethiopian patients and can be used to
differentiate between mild, moderate and severe T1R. Some limitations were noted. The
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reliability of the tool could have been tested by doing a further inter-observer validation
exercise but due to limitations in clinic staff this was not possible in this context. This has
been done previously in Bangladesh and Brazil4 and there is no reason to expect than trained
Ethiopian health care workers would score differently. VMT and SWM in the assessment of
nerve function impairment (NFI) have been shown to be reliable.8
Old NFI can constantly raise the score in the absence of active T1R. A way of adjusting
the score to take into account the effect of old NFI needs to be investigated. In the Azalep
study patients were asked whether their nerve damage had been present for more than
6 months.6 Old NFI, i.e. greater than 6 months duration, may not respond to treatment but it is
also difficult for patients to accurately time the loss of nerve function, especially when acute
NFI occurs in a nerve that already has some pre-existing permanent impairment. A set of
questions that define old nerve damage and its importance should be tested. This work needs
developing and validating
We also noticed that because the scoring system is not equally weighted, neurological
parameters are more heavily represented. This may reflect the importance of nerve function
impairment but may not adequately reflect treatment requirements. For example, it is very
difficult to associate a value of 7 (which equates to moderate T1R) to a patient who has severe
reaction in the skin of the face but nerves are unaffected. Such a patient would clinically be
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Figure 1. Box plot of Clinical Severity Scores by specialist severity classification showing medians, interquartile
ranges and minimum and maximum scores. Legend: Box-and-whisker plot of Clinical Severity Score. Participants
were classified as follows: n ¼ 20 None (CSS median ¼ 0; range:0–4; SD ¼ 1·29); n ¼ 43 Mild (CSS
median ¼ 3·0; range:0–8·5; SD ¼ 2,55); n ¼ 34 Moderate (CSS median ¼ 6·5; range 0·5–10·5; SD ¼ 2·55)
and n ¼ 38 Severe (CSS ¼ 19; range ¼ 4·5–38·5; SD ¼ 9·70).
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graded as severe and treatment would be given accordingly despite a moderate score on the
severity scale. A study assessing whether adjusting the weighting would be useful could be
carried out in conjunction with a study assessing the minimally important difference (MID)
from a patient perspective in scores derived from the scale before and after treatment. This is
important because it provides a meaningful patient centred outcome measure of change. This
study should be performed in a population in which the scale has been validated. Knowing
the magnitude of the change in score required to achieve a MID would facilitate power
calculations for clinical trials.
Although we have validated the T1R Severity Scale in Ethiopian patients with T1R,
further studies are warranted to determine its utility in future clinical studies as well as a
consensus on how to report scores in studies to allow easy comparison and pooling of results.
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Appendix 1. Clinical Severity Scale for T1Rs
Criteria 0 1 2 3 Score
A1 Degree of inflammation of skin lesions None Erythema Erythema and raised Ulceration
A2 Number of raised and/ or inflamed lesions 0 1–5 6–10 >10
A3 Peripheral oedema due to reactions None Minimal Visible but not 
affecting functions
Odema affecting 
function
A SORE
HANDS Purple 2g Monofilament scores Orange 10g Monofilament score ScoreNerves 0 0.5 1 1.5 2 2.5 3
B1 Rt 
Trigeminal
Felt Not felt
B2 Lt 
Trigeminal
Felt Not felt
B3 Rt
Ulnar
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not 
felt
3 sites
not felt
B4 Lt
Ulnar
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not 
felt
3 sites
not felt
B5 Rt
Median
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not 
felt
3 sites 
not felt
B6 Lt
Median
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not
felt
3 sites 
not felt
FEET Orange 10g Monofilament score Pink 300g Monofilament score ScoreNerves 0 0.5 1 1.5 2 2.5 3
B7 Rt. Post.
tibial 
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not 
felt
3 sites 
not felt
B8 Lt. Post.
tibial
All sites 
felt
1 sites 
not felt
2 sites 
not felt
3 sites 
not felt
1 sites not 
felt
2 sites not 
felt
3 sites 
not felt
B SCORE
Nerves 0 1 2 3 Score
C1 Rt. Facial MRC=5 MRC=4 MRC=3 MRC<3
C2 Lt.  Facial MRC=5 MRC=4 MRC=3 MRC<3
C3 Rt. Ulnar MRC=5 MRC=4 MRC=3 MRC<3
C4 Lt. Ulnar MRC=5 MRC=4 MRC=3 MRC<3
C5 Rt. Median MRC=5 MRC=4 MRC=3 MRC<3
C6 Lt. Median MRC=5 MRC=4 MRC=3 MRC<3
C7 Rt. Radial MRC=5 MRC=4 MRC=3 MRC<3
C8 Lt. Radial MRC=5 MRC=4 MRC=3 MRC<3
C9 Rt. Lateral Popliteal MRC=5 MRC=4 MRC=3 MRC<3
C10 Lt. Lateral Popliteal MRC=5 MRC=4 MRC=3 MRC<3
C SCORE
Total Score Score of A + B + C
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